Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$126.27 USD
+1.85 (1.49%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $126.18 -0.09 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$126.27 USD
+1.85 (1.49%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $126.18 -0.09 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Zacks News
EVHC vs. ADUS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EVHC vs. ADUS: Which Stock Is the Better Value Option?
Is a Summer Swoon On the Way?
by John Blank
June is historically a flat month for stocks. Any catalysts this time?
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
No Spending Lift from the Consumer? Zacks June Market Strategy
by John Blank
Real Personal Consumption expenditures has been strikingly weak in this recovery. A peak of +3.9% in Real PCE happened in Q1-2015. This growth rate has been sliding down ever since.
What Falling Estimates & Price Mean for Quorum Health (QHC)
by Zacks Equity Research
Quorum Health (QHC) is one stock you should avoid as it has seen a significant price decline and is also seeing negative earnings estimate revisions.
4 Value Stocks for Growth Investors to Enrich Portfolio
by Trina Mukherjee
On the back of an improving economy, we have zeroed in on four value stocks for growth investors, likely to enrich their portfolio.
The Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and Adverum
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and Adverum
3 Healthcare Stocks Set to Beat Q1 Earnings Estimates
by Zacks Equity Research
Elevated flu activity, aging population, high expenses, and a low tax rate would influence healthcare stocks' earnings in Q1.
Envision Healthcare (EVHC) to Report Q1 Earnings: What's Up?
by Zacks Equity Research
Envision Healthcare's (EVHC) Q1 earnings should see an upside from higher revenues at both its segments.
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
Wall Street Brushes Off Trade War Fears: Top 5 Gainers
by Tirthankar Chakraborty
The Dow climbed more than 700 points after investors downplayed fears over tariffs announced by both China and the United States.
Is Addus HomeCare (ADUS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Addus HomeCare (ADUS) could be an interesting play for investors as it is seeing solid earnings estimate revision in addition to having a robust industry rank.
Addus HomeCare (ADUS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Addus HomeCare Corporation (ADUS).
New Strong Sell Stocks for December 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for November 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
On Jun 23, we issued an updated research report on Denver, CO-based DaVita HealthCare Partners Inc. (DVA).
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment
by Zacks Equity Research
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment
Avoid Market Volatility with 5 Low-Beta Stocks
by Zacks Equity Research
In this article, we present a strategy which proves that low risky securities can also reap rewards if some specific parameters are considered.
Zacks.com featured highlights: Summer Infant, TerraVia Holdings, Addus HomeCare,Schnitzer Steel Industries and Research Frontiers
by Zacks Equity Research
Zacks.com featured highlights: Summer Infant, TerraVia Holdings, Addus HomeCare,Schnitzer Steel Industries and Research Frontiers
New Strong Buy Stocks for May 23rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Use Rising P/E Tactic to Find Out 5 Winning Stocks
by Zacks Equity Research
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.
Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.
HealthSouth Corp (HLS) Looks Good: Stock Moves 8% Higher
by Zacks Equity Research
HealthSouth Corporation (HLS) shares rose almost 8% in the last trading session.
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y
by Zacks Equity Research
Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.